Zilebesiran injection cuts BP in Phase 2 trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- KARDIA-2 trial enrolled 663 adults whose hypertension was not adequately controlled with their usual medications.
- Zilebesiran injection, added to standard therapy, produced greater blood‑pressure reductions than standard therapy alone.
- RNA interference technology in Zilebesiran blocks liver production of angiotensinogen, allowing blood vessels to relax.
- Dr. Manish Saxena led the UK portion of the study and is a senior author of the JAMA publication.
- Alnylam Pharmaceuticals funded the research, while Barts Health NHS Trust served as the top‑enrolling European site.
- KARDIA-3 trial will test Zilebesiran in patients with cardiovascular disease or high risk, and a global outcomes study later this year will assess effects on strokes and cardiovascular death.
Why it matters: Patients with resistant hypertension could achieve better control with only two injections per year, reducing reliance on daily pills and potentially lowering cardiovascular risk, while healthcare systems may see fewer medication‑related costs, fewer clinic visits, and a shift toward long‑acting therapies.
Ask SkimNews
